iECURE

aid: iecure
name: iECURE
description: iECURE is a clinical-stage genetic medicines company developing variant-agnostic, in vivo targeted gene insertion
  therapies for rare, life-threatening inherited metabolic diseases, with an initial focus on urea cycle disorders and other
  neurometabolic conditions of the liver. The company takes its name from iecur, the Latin word for liver, and was founded
  on the translational gene therapy research of James M. Wilson, M.D., Ph.D., advancing its pipeline in partnership with the
  University of Pennsylvania Gene Therapy Program. Its lead candidate, ECUR-506, pairs a dual-AAV delivery approach with Precision
  BioSciences' ARCUS nuclease to insert a functional copy of the OTC gene into the genome of infants with neonatal-onset ornithine
  transcarbamylase deficiency; it is in the OTC-HOPE study and has received FDA Orphan Drug, Rare Pediatric Disease, Fast
  Track and RMAT designations plus EU orphan designation, with clinical trial clearances in the United States, United Kingdom,
  Australia and the EU. Discovery-stage programs target citrullinemia type 1 and phenylketonuria. iECURE has raised roughly
  $115 million across a $50 million Series A in 2021 and a $65 million Series A-1 in 2022 from Versant Ventures, OrbiMed,
  Novo Holdings, the Qatar Investment Authority, LYFE Capital and Double Point Ventures. iECURE runs no developer program
  and publishes no product API, developer portal or API documentation. The only machine-readable surface reachable without
  credentials is the WordPress REST content API behind iecure.com, catalogued here.
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: true
  label: Hosted service · you call their endpoint
  confidence: high
  source:
  - openapi
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - authentication
  - rate-limits
  - security
  generated: '2026-09-03'
  method: derived
image: https://iecure.com/wp-content/uploads/iECURE_White_Logo.png
url: https://raw.githubusercontent.com/api-evangelist/iecure/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-22'
modified: '2026-08-22'
tags:
- Company
- Biotechnology
- Genetic Medicine
- Gene Editing
- Gene Therapy
- Rare Disease
- Clinical Trials
- Life Sciences
- Pharmaceuticals
- content-api
tags_raw:
- Company
- biotechnology
- genetic-medicine
- gene-editing
- gene-therapy
- rare-disease
- clinical-trials
- life-sciences
- pharmaceuticals
- content-api
apis:
- aid: iecure:iecure-com-website-wordpress-rest
  name: iECURE Website (WordPress REST)
  description: 'The public WordPress REST API (wp-json) of the iECURE website at iecure.com: the route index of the site''s
    content management system, catalogued as one site surface rather than as separate APIs.'
  baseURL: https://iecure.com/wp-json
  tags:
  - WordPress
  x-surface: platform-generated
  properties:
  - type: Documentation
    url: https://iecure.com/wp-json
  x-platform: wordpress
  x-platform-surface: rest
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://iecure.com/
- type: About
  url: https://iecure.com/about/
- type: Approach
  url: https://iecure.com/approach/
- type: Pipeline
  url: https://iecure.com/programs/
- type: News
  url: https://iecure.com/news/
- type: BlogRSS
  url: https://iecure.com/feed/
- type: Careers
  url: https://iecure.com/careers/
- type: Support
  url: https://iecure.com/contact/
- type: ExpandedAccessPolicy
  url: https://iecure.com/expanded-access-policy/
- type: PatientResources
  url: https://otc-hope.com/
- type: TermsOfService
  url: https://iecure.com/terms-of-service/
- type: PrivacyPolicy
  url: https://iecure.com/privacy-notice/
- type: CookieNotice
  url: https://iecure.com/cookie-notice/
- type: SocialMediaGuidelines
  url: https://iecure.com/social-media-community-guidelines/
- type: LinkedIn
  url: https://www.linkedin.com/company/iecure
- type: SecondaryMarket
  url: https://www.nasdaqprivatemarket.com/
- type: Authentication
  url: authentication/iecure-authentication.yml
- type: Conventions
  url: conventions/iecure-conventions.yml
- type: Conformance
  url: conformance/iecure-conformance.yml
- type: ErrorCatalog
  url: errors/iecure-problem-types.yml
- type: Lifecycle
  url: lifecycle/iecure-lifecycle.yml
- type: DataModel
  url: data-model/iecure-data-model.yml
- type: DomainSecurity
  url: security/iecure-domain-security.yml
- type: Overlay
  url: overlays/iecure-content-overlay.yaml
- type: LLMsTxt
  url: llms/iecure-llms.txt
- type: RateLimits
  url: rate-limits/iecure-rate-limits.yml
- type: Plans
  url: plans/iecure-plans-pricing.yml
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-22'
  status: enriched
  artifacts_added: 27
  pass: local-v1